Table 2 The correlation between TyG、CHG and newly developed cardiometabolic diseases during the follow-up period in CHARLS.

From: Assessment of cholesterol-HDL-glucose index in anticipating risk of cardiometabolic diseases: a comparative study with triglyceride-glucose index

 

Model 1

P

Model 2

P

Model 3

P

CHG(continuous)

2.03(1.75,2.35)

 < 0.001

2.03(1.75,2.36)

 < 0.001

1.83(1.57,2.14)

 < 0.001

CHG (Events%)

Q1 (297, 18%)

ref

 

ref

 

ref

 

Q2 (337 ,21%)

1.17(0.98, 1.39)

0.078

1.15(0.97, 1.38)

0.110

1.12 (0.94, 1.33)

0.200

Q3 (402, 25%)

1.47(1.24, 1.74)

 < 0.001

1.47 (1.24, 1.75)

 < 0.001

1.38 (1.16, 1.63)

 < 0.001

Q4 (479, 30%)

1.87(1.59, 2.21)

 < 0.001

1.87(1.59, 2.22)

 < 0.001

1.69 (1.42, 2.00)

 < 0.001

TyG(continuous)

1.55(1.41,1.70)

 < 0.001

1.56(1.42,1.72)

 < 0.001

1.46 (1.32, 1.61)

 < 0.001

TyG (Events%)

Q1 (300, 19%)

ref

 

ref

 

ref

 

Q2 (336, 21%)

1.15(0.97, 1.37)

0.110

1.14(0.96, 1.35)

0.150

1.09(0.92, 1.30)

0.300

Q3 (410, 25%)

1.49(1.26, 1.76)

 < 0.001

1.48(1.25, 1.75)

 < 0.001

1.37(1.15, 1.62)

 < 0.001

Q4 (469, 29%)

1.80(1.53, 2.12)

 < 0.001

1.82(1.54, 2.15)

 < 0.001

1.61(1.36, 1.92)

 < 0.001

  1. Model 1 was a crude model. Model 2 adjusted for age, gender, educational background, smoking status and alcohol consumption status. Model 3 further adjusted for residence, married status, sleep duration, BMI. Abbreviation: CHG, Cholesterol, high-density lipoprotein, and glucose index; TyG, triglyceride-glucose index; CI, Confidence Interval; OR, Odds Ratio.
Back to article page